Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $1,622,000.00 in Stock

Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 50,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.44, for a total transaction of $1,622,000.00. Following the sale, the chief executive officer now owns 494,117 shares in the company, valued at approximately $16,029,155.48. The trade was a 9.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ying Du also recently made the following trade(s):

• On Friday, February 28th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00.

Zai Lab Stock Up 2.9 %

ZLAB traded up $1.03 during trading on Friday, hitting $36.42. The company's stock had a trading volume of 1,312,257 shares, compared to its average volume of 750,101. Zai Lab Limited has a one year low of $13.48 and a one year high of $37.99. The firm has a market cap of $3.99 billion, a PE ratio of -13.15 and a beta of 1.08. The business's 50 day simple moving average is $28.46 and its 200-day simple moving average is $26.45.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The firm had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Equities research analysts expect that Zai Lab Limited will post -2.58 EPS for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Scotiabank started coverage on shares of Zai Lab in a research report on Friday. They set a "sector outperform" rating and a $55.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Zai Lab to a "strong-buy" rating in a research report on Tuesday. Finally, Bank of America reiterated a "neutral" rating and issued a $36.10 price target (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Institutional Trading of Zai Lab

Several institutional investors and hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in shares of Zai Lab during the 4th quarter valued at $29,000. Public Employees Retirement System of Ohio raised its position in shares of Zai Lab by 20.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company's stock valued at $484,000 after purchasing an additional 3,179 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Zai Lab by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock valued at $1,496,000 after purchasing an additional 1,200 shares during the period. Woodline Partners LP grew its stake in Zai Lab by 9.4% during the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company's stock valued at $46,089,000 after acquiring an additional 151,835 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in Zai Lab during the fourth quarter valued at $7,857,000. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.